Sanofi to cut insulin prices for uninsured from $99 to $35, matching the insulin cap coming through Congress

29 Jun 2022
endpts.com
As the House-passed bill to cap the monthly price of insulin at $35 nationwide makes its way for a Senate vote soon, Sanofi announced Wednesday morning that beginning next month it will cut the monthly price of its insulins for uninsured Americans to $35, down from $99 previously. The announcement from Sanofi, which allows the uninsured to buy one or multiple Sanofi insulins (Lantus, Insulin Glargine U-100, Toujeo, Admelog, and Apidra) at $35 for a 30-day supply effective July 1, follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure. While both the Senate and the House bills effectively cut what many of those who rely on insulin to stay alive will pay at the pharmacy counter, it doesn’t hit the prices set by the pharma manufacturers, nor does it help those who are uninsured. Majority Leader Chuck Schumer (D-NY) similarly said in March that a vote was coming soon then. Insulin juggernaut Eli Lilly — one of the big three manufacturers along with Novo Nordisk and Sanofi — previously told Endpoints News exclusively that it supports the bill. A Sanofi spokesperson similarly said the company supported the bill but with some reservations, telling Endpoints via email: Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “which limits out-of-pocket expenses for a majority of people between $0 and $10.” But the company also confirmed that some diabetics taking Sanofi’s insulins would see savings with the House bill. In 2021, about 68% of patients with commercial insurance paid $35 or less out of pocket per fill for Sanofi’s Lantus, a spokesperson added, as did about 72% of patients with Medicare Part D. But some insulin price advocates don’t think this latest Sanofi move really goes far enough. “It’s not even a band-aid on a bullet wound, because it’s a voluntary program that Sanofi can end at any time,” Laura Marston, an attorney with type 1 diabetes who advocates for lower insulin prices, told Endpoints, adding:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.